Journal of Clinical Immunology

, Volume 31, Issue 6, pp 927–935

A Prospective Study of Influenza Vaccination and a Comparison of Immunologic Parameters in Children and Adults with Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)

  • Abbas F. Jawad
  • Eline Luning Prak
  • Jean Boyer
  • Donna M. McDonald-McGinn
  • Elaine Zackai
  • Kenyetta McDonald
  • Kathleen E. Sullivan
Article

Abstract

Prior to the advent of cardiac bypass, most children with congenital cardiac anomalies and chromosome 22q11.2 deletion syndrome died. With improved technology, there is now a wave of young adults with chromosome 22q11.2 deletion syndrome requiring clinical care. Fifteen young children and 20 adults with chromosome 22q11.2 deletion had flow cytometry, functional T cell analyses, and functional B cell analyses to characterize their immune system. Subjects were vaccinated with the annual inactivated influenza vaccine, and responses were evaluated by hemagglutination inhibition titer assessment. The pattern of T cell subset abnormalities was markedly different between pediatric and adult patients. In spite of the cellular deficits observed in adults, titers produced after influenza vaccine administration were largely intact. We conclude that disruption to T cell production appears to have secondary consequences for T cell differentiation and B cell function although the clinical impact remains to be determined.

Keywords

DiGeorge syndrome homeostatic proliferation T cell senescence B cell differentiation influenza vaccine 

Supplementary material

10875_2011_9569_MOESM1_ESM.pdf (16 kb)
Supplemental Table IDemographic characteristics of subjects (PDF 15 kb)
10875_2011_9569_MOESM2_ESM.pdf (26 kb)
Supplemental Table IIB cell subsets (PDF 25.6 kb)
10875_2011_9569_MOESM3_ESM.pdf (27 kb)
Supplemental Data Fig. 1T cell responses in subjects. Peripheral blood mononuclear cells were stimulated with PMA and ionomycin to define the overall competence of memory T cells for γ-interferon production. The patients and controls do not differ significantly. Means and standard deviations are shown (PDF 26 kb)
10875_2011_9569_MOESM4_ESM.pdf (699 kb)
Supplemental Data Fig. 2B cell subsets were defined by flow cytometry. The absolute counts were obtained by multiplying the subpopulation by the CD19+ B cell count. These stacked bar graphs demonstrate the variability from person to person and define the absolute B cell counts for each population (PDF 698 kb)
10875_2011_9569_MOESM5_ESM.pdf (67 kb)
Supplemental Data Fig. 3T cell responses to influenza. Samples obtained 1–2 months after vaccination were studied for responses to influenza antigens. T cell proliferation was measured by CFSE after stimulation with intact virus (upper panel). The fraction of cells responding (% Divided) and the Proliferation Index (PI) were defined using FlowJo. The proliferation index is defined as the average number of divisions that the responding cells underwent. Means and standard deviations are shown. There were no differences between the groups. The lower panel indicates the responses to influenza antigens in an ELISPOT analysis. Means and standard deviations are shown. There are no differences between groups (PDF 67 kb)

References

  1. 1.
    DiGeorge AM. Congenital absence of the thymus and its immunological consequences: concurrance with congenital hypothyroidism. Birth Defects. 1968;4:116–21.Google Scholar
  2. 2.
    Oskarsdottir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child. 2004;89:148–51.PubMedCrossRefGoogle Scholar
  3. 3.
    McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 2011;90:1–18.CrossRefGoogle Scholar
  4. 4.
    Oskarsdottir S, Persson C, Eriksson BO, Fasth A. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr. 2005;164:146–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Vantrappen G, Devriendt K, Swillen A, Rommel N, Vogels A, Eyskens B, et al. Presenting symptoms and clinical features in 130 patients with the velo-cardio-facial syndrome. The Leuven experience. Genet Couns. 1999;10:3–9.PubMedGoogle Scholar
  6. 6.
    McDonald-McGinn DM, Kirschner R, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, et al. The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genet Couns. 1999;10:11–24.PubMedGoogle Scholar
  7. 7.
    Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet. 1997;34:798–804.PubMedCrossRefGoogle Scholar
  8. 8.
    Chinen J, Rosenblatt HM, Smith EO, Shearer WT, Noroski LM. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol. 2003;111:573–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Piliero LM, Sanford AN, McDonald-McGinn DM, Zackai EH, Sullivan KE. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood. 2004;103:1020–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Pierdominici M, Mazzetta F, Caprini E, Marziali M, Digilio MC, Marino B, et al. Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol. 2003;132:323–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Cancrini C, Romiti ML, Finocchi A, Di Cesare S, Ciaffi P, Capponi C, et al. Post-natal ontogenesis of the T-cell receptor CD4 and CD8 Vbeta repertoire and immune function in children with DiGeorge syndrome. J Clin Immunol. 2005;25:265–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Pierdominici M, Marziali M, Giovannetti A, Oliva A, Rosso R, Marino B, et al. T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome. Clin Exp Immunol. 2000;121:127–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Zemble R, Luning Prak E, McDonald K, McDonald-McGinn D, Zackai E, Sullivan K. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol. 2010;136:409–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol. 2003;4:835–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Baars PA, Maurice MM, Rep M, Hooibrink B, van Lier RA. Heterogeneity of the circulating human CD4+ T cell population. Further evidence that the CD4+CD45RA−CD27− T cell subset contains specialized primed T cells. J Immunol. 1995;154:17–25.PubMedGoogle Scholar
  16. 16.
    Tanaskovic S, Fernandez S, Price P, Lee S, French MA. CD31 (PECAM-1) is a marker of recent thymic emigrants among CD4+ T-cells, but not CD8+ T-cells or gammadelta T-cells, in HIV patients responding to ART. Immunol Cell Biol. 2010;88:321–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Sallusto F, Langenkamp A, Geginat J, Lanzavecchia A. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol. 2000;251:167–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 2011;117:63–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med. 2009;206:139–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med. 2011;208:67–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, McGhee JR. Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Int Immunol. 1994;6:11–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004;286:111–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Sullivan KE, McDonald-McGinn D, Zackai EH. CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia. Clin Diagn Lab Immunol. 2002;9:1129–31.PubMedGoogle Scholar
  27. 27.
    McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Immunologic defects in 22q11.2 deletion syndrome. J Allergy Clin Immunol. 2008;122:362–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34:108–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–58.PubMedCrossRefGoogle Scholar
  30. 30.
    Borrow P, Tough DF, Eto D, Tishon A, Grewal IS, Sprent J, et al. CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol. 1998;72:7440–9.PubMedGoogle Scholar
  31. 31.
    Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Conley ME, Beckwith JB, Mancer JF, Tenckhoff L. The spectrum of the DiGeorge syndrome. J Pediatr. 1979;94:883–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Bastian J, Law S, Vogler L, Lawton A, Herrod H, Anderson S, et al. Prediction of persistent immunodeficiency in the DiGeorge anomaly. J Pediatr. 1989;115:391–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Sullivan KE, McDonald-McGinn D, Driscoll D, Emanuel BS, Zackai EH, Jawad AF. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol. 1999;6:906–11.PubMedGoogle Scholar
  35. 35.
    Sirianni MC, Businco L, Fiore L, Seminara R, Aiuti F. T-cell subsets and natural killer cells in DiGeorge and SCID patients. Birth Defects Orig Artic Ser. 1983;19:107–8.PubMedGoogle Scholar
  36. 36.
    Jawad AF, McDonald-McGinn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001;139:715–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Gennery AR, Barge D, O'Sullivan JJ, Flood TJ, Abinun M, Cant AJ. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child. 2002;86:422–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Lavi RF, Kamchaisatian W, Sleasman JW, Martin DP, Haraguchi S, Day NK, et al. Thymic output markers indicate immune dysfunction in DiGeorge syndrome. J Allergy Clin Immunol. 2006;118:1184–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Davis CM, Kancherla VS, Reddy A, Chan W, Yeh HW, Noroski LM, et al. Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome. J Allergy Clin Immunol. 2008;122:1194–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, et al. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003;102:1121–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Markert ML, Watson TJ, McLaughlin TM, McGuire CA, Ward FE, Kostyu D, et al. Development of T-cell function after post-natal thymic transplanation for DiGeorge syndrome. Am J Hum Genet. 1995;57:A14.Google Scholar
  42. 42.
    Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, et al. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol. 2004;113:734–41.PubMedCrossRefGoogle Scholar
  43. 43.
    Markert ML, Boeck A, Hale LP, Kloster AL, McLaughlin TM, Batchvarova MN, et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med. 1999;341:1180–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol. 2008;20:1189–99.PubMedCrossRefGoogle Scholar
  45. 45.
    Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med. 2003;197:451–60.PubMedCrossRefGoogle Scholar
  47. 47.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Elder DA, Kaiser-Rogers K, Aylsworth AS, Calikoglu AS. Type I diabetes mellitus in a patient with chromosome 22q11.2 deletion syndrome. Am J Med Genet. 2001;101:17–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Etzioni A, Pollack S. Autoimmune phenomena in DiGeorge syndrome [letter; comment]. Israel J Med Sci. 1994;30:853.PubMedGoogle Scholar
  50. 50.
    Davies JK, Telfer P, Cavenagh JD, Foot N, Neat M. Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol. 2003;25:195–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD, et al. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet A. 2005;138:307–13.PubMedGoogle Scholar
  52. 52.
    Finocchi A, Di Cesare S, Romiti ML, Capponi C, Rossi P, Carsetti R, et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). Pediatr Allergy Immunol. 2006;17:382–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Smith CA, Driscoll DA, Emanuel BS, McDonald-McGinn DM, Zackai EH, Sullivan KE. Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol. 1998;5:415–7.PubMedGoogle Scholar
  54. 54.
    Junker AK, Driscoll DA. Humoral immunity in DiGeorge syndrome. J Pediatr. 1995;127:231–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Abbas F. Jawad
    • 1
  • Eline Luning Prak
    • 2
  • Jean Boyer
    • 3
  • Donna M. McDonald-McGinn
    • 1
  • Elaine Zackai
    • 1
  • Kenyetta McDonald
    • 1
  • Kathleen E. Sullivan
    • 1
    • 4
  1. 1.Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Marlene and Stewart Greenebaum Cancer CenterUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  4. 4.Division of Allergy ImmunologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations